SMJ Saratov Medical Journal
ISSN 2712-8253, Saratov Medical Journal
2024. Volume 5. Issue 2. Article CID e0202
DOI: 10.15275/sarmj.2024.0202

Review

Advances in dermatology research: A comprehensive literature review

Kirolos Eskandar
✉ kiroloss.eskandar@gmail.com

Diakonie Klinik Mosbach, Germany

Accepted 25 May 2024

Abstract:
In recent years, the field of dermatology has seen significant advances in our understanding of disease pathogenesis, diagnostic techniques, and therapeutic interventions. The objective of this literature review is to provide an overview of ten key subtopics in contemporary dermatology research. First, I examined cutting-edge developments in skin cancer detection and treatment, acne and psoriasis management strategies, and the evolving therapeutic landscape for atopic dermatitis. Additionally, we delve into the clinical significance of skin manifestations associated with systemic diseases and analyze emerging trends in cosmetic dermatology. Further on, we discuss innovations in wound healing, diagnosis and treatment of hair disorders, and dermatological conditions unique to pediatric patients. Finally, we explore the role of telemedicine in dermatology practice, highlighting its potential to revolutionize patient care and access to specialty services. Through a synthesis of the current literature, this review offers insight into forefront dermatology research and emphasizes the importance of continued innovation to improve patient outcomes and quality of care.

Keywords: dermatology, skin cancer, therapeutics, telemedicine, pediatric dermatology.

Cite as: Eskandar K. Advances in dermatology research: A comprehensive literature review. *Saratov Medical Journal* 2024; 5 (2): e0202. https://doi.org/10.15275/sarmj.2024.0202

Introduction

Dermatology, the branch of medicine concerned with the diagnosis and treatment of skin diseases, covers a wide range of conditions: from common disorders such as acne to life-threatening ailments such as melanoma. Over the past few decades, the field of dermatology has seen significant advances in understanding disease pathogenesis, diagnostic techniques, and therapeutic interventions [1].

Skin cancer, including melanoma and non-melanoma skin malignance, is a major public health problem worldwide. Recent research has focused on improving early diagnosis methods and exploring innovative treatment options to improve patient outcomes [2]. Similarly, treatment of chronic inflammatory skin diseases such as psoriasis and atopic dermatitis has evolved with the introduction of targeted biologic-based therapies and small molecule inhibitors [3, 4].

The relationship between dermatological manifestations and systemic diseases has received increasing attention in recent years. Cutaneous manifestations often serve as important clinical indicators of underlying systemic diseases, requiring a multidisciplinary approach to diagnosis and treatment [5]. Additionally, the field of cosmetic dermatology has seen a surge in demand for minimally invasive procedures, injectables, and laser treatments, spurring research into new techniques and technologies [6].

Advances in wound healing have also become a focus of dermatology research, with an increasing emphasis on the development of innovative dressings, growth factors, and tissue engineering approaches [7]. Additionally, the diagnosis and treatment of hair disorders, including alopecia areata and androgenetic alopecia, continue to evolve with the advent of new therapeutic options [8].

Pediatric dermatology remains a subspecialty within the field, dealing with dermatological conditions unique to children, such as eczema, diaper dermatitis, and genetic skin disorders [9]. Finally, the integration of telemedicine into dermatology practice has gained prominence, offering opportunities to improve patient access to care, particularly in underserved or remote areas [10].

The objective of this literature review is to provide an overview of recent advances in dermatology across the ten key subtopics. By synthesizing current research findings, this review seeks to clarify the evolving landscape of dermatology care and its impact on clinical practice and patient outcomes

Methodology

In conducting this review on advances in dermatology research, I employed a systematic approach to ensure the inclusion of high-quality relevant studies. The methodology for selecting and analyzing published sources is outlined as follows.

Databases and search strategy

A literature search was conducted across several major databases including PubMed, Scopus, Web of Science, and Embase. These databases were chosen for their broad coverage of biomedical and clinical research, allowing for a thorough examination of the existing literature. The search was limited to articles published between January 2018 and March 2024 to capture the most recent advances in dermatology research.

Keywords and search terms

A combination of keywords and Medical Subject Headings (MeSH) terms were used to ensure a comprehensive search. Keywords included but were not limited to dermatology advances, skin cancer treatment, psoriasis therapy, atopic dermatitis treatment, biologic-based therapies, neuroendocrine signaling in the skin, and vitamin D synthesis in the skin. Boolean operators (AND, OR) were used to refine and expand the search results.

Inclusion and exclusion criteria

To ensure the relevance and quality of the studies included in this review, the following specific inclusion and exclusion criteria were applied.

Inclusion criteria:

- Original peer-reviewed research articles, systematic reviews, and meta-analyses;
- Studies focusing on advances in dermatological treatments, diagnostic methods, or underlying biological mechanisms;
- Articles published in English;
- Studies with a clear focus on human subjects or clinically relevant animal models.

Exclusion criteria:

- Case reports, editorials, and commentaries;
- Studies with insufficient methodological rigor or those lacking clear results related to advances in dermatology;
- Articles not focused on specific subfields of interest in dermatology (e.g., studies focused solely on cosmetic dermatology without clinical implications).

Selection process

The initial database search yielded a large number of potentially relevant studies. They were then subjected to a multi-stage screening process:

1. Title and abstract screening (the titles and abstracts of all retrieved articles were reviewed to exclude studies that clearly did not meet the inclusion criteria);

2. Full text review (the remaining articles underwent full text review to further assess their relevance and quality);

3. Final selection (studies that met all inclusion criteria and provided significant insights on advances in the field of dermatology were included in the final review).

A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart (*Figure*) was constructed to visually represent the selection process. This chart details the number of articles identified, screened, assessed for eligibility, and included in the final review, ensuring transparency and reproducibility in the literature selection process.



Figure. PRISMA flow diagram

Results

Detection and treatment of skin cancer

Skin cancer, a common and potentially fatal disease, is a major global health concern. With its various types including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), the need for effective detection and treatment strategies is paramount [11]. Recent years have seen significant advances in both early detection methods and therapeutic approaches, dramatically changing the skin cancer treatment landscape.

Early detection is critical to mitigating the adverse outcomes associated with skin cancer progression. Dermatoscopy, a noninvasive imaging technique, has become the cornerstone of early melanoma diagnosis. By magnifying the skin surface and visualizing subsurface structures, dermatoscopy helps physicians differentiate between benign and malignant lesions [12]. Using artificial intelligence (AI), dermatoscopy has made advances in automated lesion analysis, which improves diagnostic accuracy [13]. Reflectance confocal microscopy (RCM) complements dermatoscopy by providing visualization of skin lesions at the cellular level, allowing real-time assessment of morphological features [14]. Together, these technologies have opened a new era of accurate diagnosis, allowing clinicians to intervene early in disease progression.

Beyond diagnosis, innovative treatments have revolutionized the management of skin cancer, especially metastatic melanoma. Targeted therapies such as BRAF inhibitors and immune checkpoint inhibitors have demonstrated remarkable efficacy in improving survival outcomes [15]. Additionally, intralesional therapies, including oncolytic virus therapy and intralesional immunotherapy, offer localized treatment options with reduced systemic toxicity [16]. Mohs micrographic surgery (MMS) remains the gold standard for non-melanoma skin cancers, providing high rates of favorable outcomes and tissue preservation through meticulous margin assessment [17]. Recent advances in MMS techniques, including frozen section immunofluorescence mapping, have further optimized surgical outcomes by improving tumor margin assessment [18].

In recent years, immunotherapy has emerged as a promising treatment option for advanced melanoma. Immune checkpoint inhibitors such as pembrolizumab and ipilimumab have shown remarkable efficacy in improving survival outcomes in patients with metastatic melanoma [19]. These agents target key immune checkpoints – e.g.,

programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4), triggering an antitumor immune response and resulting in sustained tumor regression [20]. Combination therapies, including dual immune checkpoint blockade and immune checkpoint inhibitors with targeted agents, have further improved treatment responses and prolonged survival in patients with advanced melanoma [21].

The role of vitamin D signaling in melanoma has attracted increasing attention, especially in the context of its potential impact on tumor progression and patient outcomes. Vitamin D, traditionally known for its role in calcium homeostasis, is involved in the regulation of cell proliferation, differentiation, and apoptosis – processes that are critical in the context of melanoma [22, 23]. Recent studies have shown that vitamin D may exert a protective effect against melanoma by modulating the expression of genes involved in cell cycle regulation and immune responses [22]. In particular, the active form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D], binds to the vitamin D receptor (VDR), which is expressed in melanoma cells. This interaction influences the transcription of genes that regulate cell growth and immune surveillance, potentially suppressing melanoma progression [23].

Novel therapeutic strategies have explored the potential of vitamin D analogs in the treatment of melanoma. These analogs, designed to maximize the antitumor effects of vitamin D while minimizing its calcemic activity, have shown promising results in preclinical models [24]. Additionally, combining vitamin D with existing immunotherapies, such as immune checkpoint inhibitors, is being explored as a strategy to improve the efficacy of treatment regimens and overcome resistance mechanisms in melanoma [22]. Although clinical data are still evolving, these results suggest that vitamin D signaling may play an important role in melanoma biology and open new avenues for therapeutic intervention [25].

Neuroendocrine signaling in the skin

The skin is not only a protective barrier but also a dynamic organ involved in complex neuroendocrine signaling that plays a critical role in maintaining skin homeostasis and responding to environmental stressors. The concept of skin as a neuroendocrine organ has attracted increasing attention, especially with the discovery of neuropeptides that mediate communication between the nervous, endocrine and immune systems in the skin [26]. Neuropeptides such as substance P, calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) are synthesized by cells residing in the skin, including keratinocytes, melanocytes and immune cells, and are involved in the regulation of various physiological processes [27, 28].

Recent studies have highlighted the importance of neuropeptides in modulating skin immune responses, influencing both innate and adaptive immunity [28]. Neuropeptides can modulate the function of immune cells (e.g., T cells, macrophages and dendritic cells), thereby affecting inflammatory pathways and contributing to the pathogenesis of inflammatory skin diseases such as psoriasis, atopic dermatitis, and rosacea [29]. The interaction between neuropeptides and their receptors on skin cells also plays a key role in wound healing, pain perception, and response to ultraviolet (UV) radiation, which are critical for maintaining skin integrity [30, 31].

Among significant advances in this field, it is worth noting the understanding of hypothalamic-pituitary-adrenal (HPA) axis signaling in the skin [29]. Local production of corticotropin-releasing hormone (CRH) in the skin can activate this axis, leading to the secretion of cortisol, which in turn modulates local immune responses and affects skin homeostasis [28]. Dysregulation of this local HPA axis has been linked to a variety of skin diseases, suggesting that targeting neuroendocrine pathways may offer new therapeutic strategies [28].

Furthermore, the role of neuropeptides in the stress response is becoming increasingly evident. Chronic stress has been shown to exacerbate inflammatory skin diseases by altering neuropeptide expression and disrupting the delicate balance of neuroimmune interactions in the skin [27]. For instance, stress-induced release of substance P has been linked to exacerbation of psoriasis and atopic dermatitis, highlighting the therapeutic potential of neuropeptide antagonists in the treatment of stress-related skin diseases [32].

The clinical implications of these findings are profound and open new avenues for the treatment of inflammatory skin diseases. Targeting neuroendocrine pathways, either by modulating neuropeptide activity or by correcting impaired HPA axis signaling, may provide more effective and personalized treatment options for patients with chronic skin diseases [28]. As research in this area continues to evolve, it may pave the way for new therapeutic interventions that target neuroimmunoendocrine circuitry in the skin, ultimately improving patient outcomes [28].

Management of acne vulgaris

Acne vulgaris, a common inflammatory skin disorder, affects millions of people worldwide, with a significant impact on quality of life and psychological well-being. Effective treatment strategies encompass a range of topical and systemic therapies, as well as novel therapies that target the multifactorial pathogenesis of acne [33].

Topical therapies often constitute the first-line approach for mild to moderate acne vulgaris. They work via targeting multiple pathogenic factors, including inflammation, hyperkeratinization, and Propionibacterium acnes proliferation. Retinoids such as tretinoin and adapalene are the cornerstones of treatment, promoting normalization of follicular keratinization and reducing formation of comedones [34]. Benzoyl peroxide, a potent antimicrobial agent, is effective in reducing P. acnes colonization and inflammatory lesions when used alone or in combination with other topical agents [35]. In addition, topical antibiotics such as clindamycin and erythromycin have anti-inflammatory and antibacterial effects, making them valuable adjuncts in the treatment of inflammatory acne lesions [36].

For moderate to severe acne or cases refractory to topical therapy, systemic treatment may be indicated. Oral antibiotics such as tetracycline derivatives (e.g., doxycycline and minocycline) are commonly prescribed to control P. acnes proliferation and reduce inflammation [37]. However, long-term antibiotic use raises concerns about antibiotic resistance and gastrointestinal side effects, necessitating prudent prescribing practices and combination therapy. Oral contraceptives containing estrogen and progestin hormones are another effective option for the treatment of acne in women, as they modulate sebum production and reduce androgen stimulation of the sebaceous glands [38].

In recent years, several new treatment modalities have gained attention for their potential in the treatment of acne. Photodynamic therapy (PDT), which involves activating photosensitizing agents with specific wavelengths of light, has demonstrated efficacy in reducing inflammatory acne lesions and P. acnes colonization [39]. Additionally, laser and light therapies, including fractional laser resurfacing and intense pulsed light (IPL) therapy, offer alternative methods for targeting acne lesions and improving skin texture and tone [40]. Also, new topical agents (nitric oxide-releasing compounds and retinoid formulations with improved tolerability profiles) are under study for their potential role in the treatment of acne [41].

Psoriasis therapy

Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by erythematous plaques with silvery scales. Recent advances in the understanding of psoriasis pathogenesis have led to the development of new therapies aimed at targeting specific immune pathways involved in the pathogenesis of the disease [42].

The pathogenesis of psoriasis is multifactorial, involving dysregulation of both innate and adaptive immune responses. Key players in the pathogenesis of psoriasis include T lymphocytes, dendritic cells, and keratinocytes driven by proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin 23 (IL-23), and interleukin 17 (IL-17) [43]. Dysregulation of T cell activation results in the release of cytokines that promote keratinocyte proliferation and inflammation, thereby resulting in the characteristic psoriatic plaques [44].

Therapies based on biologics have revolutionized the treatment of moderate to severe psoriasis by targeting key immune pathways involved in the pathogenesis of the disease. TNF-α inhibitors (etanercept, adalimumab and infliximab) have demonstrated efficacy in reducing disease severity and improving quality of life in patients with psoriasis [45]. These biologics work by neutralizing TNF-α, a proinflammatory cytokine involved in the pathogenesis of psoriasis.

In addition to TNF-α inhibitors, interleukin 17 (IL-17) inhibitors have emerged as a promising therapeutic option for the treatment of psoriasis. IL-17-targeted drugs such as secukinumab and ixekizumab have shown superior efficacy compared to placebo and have been associated with significant improvements in psoriasis symptoms and quality of life [46]. Similarly, interleukin 23 (IL-23) inhibitors such as ustekinumab, guselkumab, and risankizumab have shown efficacy in the treatment of psoriasis by targeting the IL-23/IL-17 axis, a key pathway in the pathogenesis of psoriasis [47].

In addition to biologic-based therapies (*Table*), small molecule inhibitors offer an alternative approach to the treatment of psoriasis by targeting intracellular signaling pathways involved in the pathogenesis of the disease. Janus kinase (JAK) inhibitors such as tofacitinib and baricitinib have demonstrated efficacy in the treatment of psoriasis by inhibiting cytokine signaling pathways involved in T cell activation and inflammation [48]. Phosphodiesterase 4 (PDE4) inhibitors such as apremilast modulate intracellular cyclic adenosine monophosphate (cAMP) levels, resulting in anti-inflammatory effects and improvement in psoriasis symptoms.

The psoriasis treatment landscape has changed significantly with the advent of biologic therapies and new topical therapies aimed at improving patient outcomes. A recent addition to the pool of topical treatment agents is roflumilast, a selective phosphodiesterase 4 (PDE4) inhibitor. Roflumilast works by inhibiting the breakdown of cyclic adenosine monophosphate (cAMP), resulting in decreased production of proinflammatory cytokines and subsequent suppression of the inflammatory processes associated with psoriasis [49].

Clinical trials have demonstrated the efficacy of topical roflumilast in the treatment of mild to moderate plaque psoriasis. In a pivotal Phase 3 study, a significant proportion of patients treated with roflumilast cream achieved clear or near clear Investigator Global Assessment (IGA) scores, with significant improvements in plaque thickness, scaling, and erythema compared with placebo [50]. Moreover, roflumilast was well tolerated and its safety profile was comparable to that of other topical agents, making it a promising option for patients, particularly those with sensitive skin or those who prefer topical treatment over systemic therapy.

Given its efficacy and safety, roflumilast has been included in the latest psoriasis treatment guidelines, offering a new option for patients with mild to moderate disease who require effective and convenient therapy. It is particularly useful for patients for whom systemic treatment is contraindicated or who wish to minimize the risk of systemic side effects [51].

Atopic dermatitis

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disease characterized by pruritic and eczematous lesions affecting both children and adults. Recent studies have provided insights into the complex pathophysiology of AD, highlighting the role of immune dysregulation, barrier dysfunction, and genetic predisposition [43].

The pathogenesis of AD involves a complex interplay between genetic, immunological, and environmental factors. Mutations in genes encoding proteins involved in skin barrier function, such as filaggrin, disrupt the epidermal barrier, leading to increased transepidermal water loss and susceptibility to allergens and environmental irritants [44]. Dysregulation of the immune response, characterized by Th2-driven inflammation and impaired regulatory T cell function, further contributes to the development and persistence of AD [40]. In addition, environmental factors such as exposure to allergens, pollutants, and microbial dysbiosis play a role in triggering and exacerbating AD flares [46].

Treatment of AD aims to alleviate symptoms, restore the skin barrier, and modulate the underlying immune dysregulation. Topical corticosteroids and calcineurin inhibitors remain first-line treatments for acute flares, providing rapid relief of inflammation and pruritus [47]. However, concerns about long-term safety and potential side effects have prompted the exploration of alternative therapeutic strategies.

Table. **Biologic-based therapies for psoriasis: their targets, clinical efficacy and common side effects**

Biologic	Target	Clinical efficacy	Common side effects
Adalimumab	TNF-α	PASI 75 response in 71-80% of patients	Injection site reactions, infections, headaches
Etanercept	TNF-α	PASI 75 response in 47-49% of patients	Injection site reactions, respiratory infections, headaches
Infliximab	TNF-α	PASI 75 response in 75-80% of patients	Infusion-related reactions, infections, elevated levels of liver enzymes
Ustekinumab	IL-12/IL-23	PASI 75 response in 67-76% of patients	Infections, headaches, back pain, fatigue
Secukinumab	IL-17A	PASI 75 response in 77-81% of patients	Infections, diarrhea, nasopharyngitis, headaches
Ixekizumab	IL-17A	PASI 75 response in 82-89% of patients	Infections, injection site reactions, headaches
Brodalumab	IL-17 receptor	PASI 75 response in 83-85% of patients	Infections, neutropenia, suicidal ideation
Guselkumab	IL-23	PASI 90 response in 73-77% of patients	Infections, joint pain, injection site reactions
Risankizumab	IL-23	PASI 90 response in 73-81% of patients	Infections, fatigue, headache, injection site reactions
Tildrakizumab	IL-23	PASI 75 response in 61-66% of patients	Infections, injection site reactions, diarrhea

PASI 75/90, percentage of patients achieving a 75%/90% improvement in the psoriasis area and severity index (PASI) score; *TNF-α,* tumor necrosis factor alpha; *IL-12/IL-23, IL-17A, IL-23,* interleukin-12/23, interleukin-17A, interleukin-23, respectively.

Therapies based on using biologics targeting specific immune pathways involved in the pathogenesis of AD have shown promise in the treatment of moderate to severe AD. Dupilumab, a monoclonal antibody targeting the alpha subunit of the interleukin 4 receptor, has demonstrated efficacy in reducing AD severity and improving quality of life in patients with poorly controlled disease [48]. Similarly, other biologics targeting key cytokines involved in AD inflammation, such as interleukin 13 and interleukin 31, are under investigation and have potential for future therapeutic use [52].

In addition to biologics, immunomodulators offer alternative therapeutic options for the treatment of AD. JAK inhibitors such as baricitinib and upadacitinib modulate intracellular signaling pathways involved in the inflammatory response, providing a targeted approach to the treatment of AD [53]. Similarly, PDE4 inhibitors such as crisaborole exert anti-inflammatory effects by inhibiting the production of proinflammatory cytokines, offering a nonsteroidal treatment option for AD [54].

The treatment of atopic dermatitis has made significant advances with the advent of topical ruxolitinib, a JAK inhibitor that targets the JAK-STAT signaling pathway involved in the inflammatory response characteristic of atopic dermatitis. Ruxolitinib cream was recently approved by the FDA for the treatment of mild to moderate AD in non-immunocompromised patients aged 12 years and older, marking an important advance in the topical treatment of this condition [49].

Ruxolitinib exerts its effects by inhibiting JAK1 and JAK2, resulting in reduced levels of inflammatory cytokines such as IL-4, IL-13, and interferon gamma (IFN-γ), which are implicated in the pathogenesis of AD. The clinical efficacy of ruxolitinib cream has been demonstrated in several Phase 3 studies, where patients treated with ruxolitinib achieved significant improvements in Eczema Area and Severity Index (EASI) and pruritus scores vs. those treated with a vehicle cream [50].

Importantly, ruxolitinib cream has shown a favorable safety profile with minimal systemic absorption and a low incidence of adverse events, making it a suitable option for long-term use in the treatment of AD. Its introduction into clinical practice provides a valuable tool for dermatologists, especially for patients who do not respond adequately to conventional treatments or who experience adverse effects from corticosteroids and calcineurin inhibitors [49].

Cutaneous manifestations of systemic diseases

Skin manifestations often serve as important clinical clues to the identification of underlying systemic diseases, providing valuable information for diagnosis, prognosis, and treatment. Dermatological manifestations associated with systemic diseases cover a wide range of conditions, including but not limited to lupus erythematosus, diabetes mellitus, and autoimmune disorders [55].

Skin involvement is common in systemic lupus erythematosus (SLE), with up to 85% of patients experiencing dermatological manifestations during the course of their disease [56]. Cutaneous lupus erythematosus (CLE) encompasses a heterogeneous group of skin diseases, ranging from acute cutaneous lupus erythematosus (ACLE) with transient erythematous macules and papules to chronic cutaneous lupus erythematosus (CCLE) with discoid lesions and scarring [57]. In addition, subacute cutaneous lupus erythematosus (SCLE) presents with non-scarring psoriasis-like or annular plaques, often induced by photosensitivity [58].

Diabetes mellitus (DM) is associated with a variety of cutaneous manifestations reflecting both microvascular and macrovascular complications of the disease. Diabetic dermopathy characterized by hyperpigmented atrophic macules typically on the shins is a common cutaneous finding in patients with long-standing DM [59]. Other skin manifestations of DM include necrobiosis lipoidica diabeticorum, diabetic foot ulcers and candidal intertrigo, highlighting the importance of skin evaluation in patients with DM for early detection and treatment of complications [60].

Autoimmune disorders encompass a diverse group of conditions characterized by immune-mediated tissue injury. Cutaneous manifestations are often prominent features of autoimmune diseases, providing diagnostic clues and prognostic indicators. For example, dermatomyositis is characterized by heliotrope rash, Gottron papules, and

proximal muscle weakness, while scleroderma is associated with sclerodactyly, Raynaud's phenomenon, and digital ulcers [61]. Additionally, autoimmune blistering diseases (such as pemphigus and bullous pemphigoid) are manifested with blisters and erosions at the mucocutaneous level, necessitating prompt diagnosis and initiation of immunosuppressive therapy [62].

Cutaneous manifestations of systemic diseases often have significant clinical implications, serving as early indicators of underlying pathology and guiding therapeutic interventions. Dermatologists play a critical role in the multidisciplinary management of patients with systemic diseases, collaborating with rheumatologists, endocrinologists and other specialists to optimize patient care and outcomes [63]. Treatment strategies may include systemic immunosuppressive therapy, targeted biologics, and supportive measures aimed at controlling inflammation, preventing complications, and improving quality of life [64].

Trends in cosmetic dermatology

Cosmetic dermatology continues to evolve rapidly, driven by advances in technology and increasing patient demand for minimally invasive procedures to improve aesthetic appearance. New trends in cosmetic dermatology cover a wide range of interventions, including minimally invasive procedures, injectables, and laser treatments aimed at improving skin texture, tone, and overall youthfulness [65].

Minimally invasive procedures such as microneedling, chemical peels, and microdermabrasion have gained popularity due to their ability to rejuvenate the skin with minimal downtime and side effects [66]. Microneedling, also known as collagen induction therapy, involves the use of fine needles to create microtraumas in the skin, stimulating collagen production and improving skin texture and elasticity [67]. Chemical peels use various chemical agents, such as alpha hydroxy acids (AHAs) and trichloroacetic acid (TCA), to exfoliate the outer layers of the skin, promoting cell turnover and reducing the appearance of fine lines, wrinkles, and hyperpigmentation [68]. Similarly, microdermabrasion involves mechanically exfoliating the skin using a diamond-tipped wand or crystal-based device, resulting in smoother and more radiant skin [69].

Injectable procedures, including botulinum toxin (Botox®) and dermal fillers, remain cornerstones of cosmetic dermatology interventions due to their ability to temporarily reduce wrinkles, restore volume, and improve facial contours [70]. Botox® injections selectively inhibit muscle contractions, thereby reducing dynamic wrinkles such as crow's feet and forehead lines, while dermal fillers such as hyaluronic acid-based products restore lost volume and sculpt facial features such as the cheeks, lips, and nasolabial folds [71].

Laser and energy-based devices have revolutionized the field of cosmetic dermatology by offering precise and targeted treatments for a variety of skin problems, including photoaging, pigmentation, and vascular lesions [64]. Fractional laser resurfacing, intense pulsed light (IPL), and laser hair removal are some of the most commonly performed laser procedures in cosmetic dermatology, providing significant improvements in skin texture, tone and overall appearance [68].

Safety and efficacy remain paramount considerations in the field of cosmetic dermatology, with ongoing research and clinical studies aimed at optimizing treatment outcomes and minimizing adverse effects [69]. Patient education and informed consent are essential aspects of the cosmetic dermatology consultation process, ensuring that patients have realistic expectations and understand the potential risks and benefits of cosmetic interventions [70].

Innovations in wound healing

Wound healing is a complex biological process involving a number of coordinated events including inflammation, proliferation, and remodeling aimed at restoring tissue integrity and function. Despite advances in wound care, chronic wounds such as diabetic ulcers and pressure ulcers remain a significant clinical challenge requiring exploration of new approaches to improve wound healing and patient outcomes [71].

Innovative dressings play a key role in contemporary wound care by providing a favorable environment for optimal healing. Hydrocolloid dressings, foam dressings, and hydrogels are some of the most commonly used modern dressings, offering benefits such as moisture retention, exudate management, and maintaining a moist wound environment conducive to healing [72]. Additionally, antimicrobial dressings containing silver or iodine have been shown to be effective in reducing bacterial load and preventing wound infection, thereby promoting wound healing [73].

Growth factors play a key role in regulating the wound healing process by stimulating cell proliferation, migration, and differentiation. Platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF) are among the growth factors involved in wound healing, with therapeutic potential in stimulating angiogenesis, collagen synthesis, and tissue regeneration [74]. Growth factor-based therapies including recombinant growth factors and platelet-rich plasma (PRP) injections have shown promise in accelerating wound healing and improving chronic wound outcomes.

Tissue engineering techniques offer innovative approaches to wound healing by providing scaffolds, cells, and bioactive factors to stimulate tissue regeneration. Biomaterial scaffolds, such as collagen matrices and synthetic polymers, serve as temporary scaffolds for cell infiltration and tissue ingrowth, facilitating wound closure and remodeling. Additionally, cell-based therapies, including mesenchymal stem cells (MSCs) and keratinocytes, have been investigated for their regenerative potential in promoting wound healing and tissue repair [75].

Innovations in wound healing also extend to new technologies such as negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBOT), which offer additional strategies to promote wound closure and tissue regeneration [66]. NPWT applies controlled negative pressure to the wound bed, promoting granulation tissue formation and wound contraction, while HBOT delivers high-pressure oxygen to improve tissue oxygenation and promote angiogenesis [76].

Hair disorders and their treatment

Hair disorders encompass a wide spectrum of conditions affecting the scalp and hair follicles, ranging from alopecia areata and androgenetic alopecia to hirsutism. These disorders can have significant psychosocial consequences by affecting self-esteem and quality of life. Recent therapeutic advances have expanded treatment options for patients with hair disorders, offering hope for improved outcomes and management strategies [73].

Alopecia areata is an autoimmune disorder characterized by patchy, non-scarring hair loss resulting from immune-mediated destruction of hair follicles. Recent studies have elucidated the underlying immunopathogenesis of alopecia areata, highlighting the role of T-cell-mediated inflammation and cytokine dysregulation [74]. Treatment options for alopecia areata include topical corticosteroids, intralesional corticosteroid injections, and systemic immunosuppressants such as oral corticosteroids, methotrexate, and JAK inhibitors [77]. Newer treatments targeting specific immune pathways such as interleukin 2 and interleukin 15 blockade are under study and show promise for future treatment [76].

Androgenetic alopecia, also known as female (or male) pattern hair loss, is an inherited disorder characterized by progressive hair thinning and miniaturization of hair follicles as a result of genetic and hormonal factors. Recent advances in the understanding of androgenetic alopecia have focused on the role of androgen receptors, 5-alpha reductase activity, and the scalp microenvironment in hair follicle miniaturization [77]. Treatment options for androgenetic alopecia include topical minoxidil, oral finasteride, and low-level laser therapy (LLLT), which aim to stimulate hair growth and prolong the anagen phase of the hair growth cycle [78]. New therapies targeting novel pathways such as prostaglandin analogs and Wnt/β-catenin signaling offer potential targets for future treatment development [70].

Hirsutism is characterized by excessive hair growth in androgen-sensitive areas such as the face, chest, and back, in a male-pattern distribution. Treatment of hirsutism involves correcting the underlying hormonal imbalance, often through pharmacological interventions targeting androgen production or action. Oral contraceptives, antiandrogens, and insulin-sensitizing agents such as spironolactone, cyproterone acetate, and metformin are commonly used to suppress androgen levels and reduce hirsutism [71]. Laser hair removal and electrolysis offer effective long-term solutions to reduce unwanted hair growth, complementing drug therapy in the treatment of hirsutism [72].

Pediatric dermatology

Pediatric dermatology encompasses the diagnosis and treatment of dermatological conditions unique to children, ranging from common conditions such as eczema and diaper rash to rare genetic skin disorders. These conditions can have a significant impact on the health and well-being of children, requiring specialized care and individualized treatment approaches [73].

Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disorder characterized by itchy, erythematous patches and plaques. Eczema often presents in infancy or early childhood, primarily on flexural surfaces such as the elbows and knees. The pathogenesis of eczema involves a complex interaction of genetic predisposition, immune dysregulation, and environmental factors [74]. Treatment of eczema is aimed at maintaining skin hydration, minimizing inflammation, and preventing flares. Emollients, topical corticosteroids, calcineurin inhibitors, and antihistamines are some of the mainstays of therapy for eczema in children [78].

Diaper dermatitis, or diaper rash, is a common inflammatory skin condition affecting the diaper area of infants and young children. Prolonged exposure to moisture, friction, and irritants such as urine and feces can lead to irritation and breakdown of the skin, resulting in erythema, swelling, and sometimes ulceration. Prevention and treatment of diaper dermatitis include frequent diaper changes, gentle cleansing of the diaper area, and application of barrier creams or ointments containing zinc oxide or petrolatum [79].

Genetic skin diseases encompass a wide range of conditions characterized by inherited mutations that affect the skin and its appendages. Examples of genetic skin disorders in children include epidermolysis bullosa, ichthyosis, and congenital melanocytic nevi. These conditions are often present at birth or in early childhood and can have significant dermatologic and systemic manifestations [80]. Treatment of genetic skin disorders may involve multidisciplinary care, supportive measures, and targeted therapies aimed at relieving symptoms and improving quality of life [81].

Telemedicine in dermatology

Telemedicine, the use of telecommunications technology to deliver healthcare services remotely, has become a valuable tool in dermatology practice, offering potential benefits in patient care, diagnostic accuracy, and access to specialty services, especially in remote or underserved areas [82].

The introduction of telemedicine in dermatology has contributed to greater accessibility to dermatology care, overcoming geographic barriers, and improving patient access to specialty services. Patients living in rural or underserved areas where dermatologists may be scarce can now consult with an expert and receive timely diagnosis and treatment recommendations through telemedicine platforms [83].

Telemedicine in dermatology has also been shown to improve patient convenience and satisfaction by eliminating the need to travel to healthcare facilities and reducing wait times for appointments. Patients can conveniently consult with dermatologists from the comfort of their homes, leading to improved patient engagement and compliance with treatment plans [84].

Moreover, telemedicine has demonstrated its usefulness in facilitating timely dermatological consultations, particularly in urgent or emergency settings. Use of telemedicine in dermatology allows for rapid assessment of skin conditions, allowing dermatologists to evaluate the urgency of cases and provide timely intervention, thereby reducing unnecessary emergency department visits and hospitalizations [85].

While telemedicine offers numerous benefits, challenges remain, particularly regarding diagnostic accuracy and patient privacy. Reliance on digital imaging and remote assessment may limit the ability to perform comprehensive physical examinations, which may result in diagnostic inaccuracies or missed results. Additionally, concerns regarding data security and patient privacy must be

addressed to ensure compliance with health regulations and protect patient privacy [86].

Knowledge gaps and directions of future research

Future dermatology research should address several key areas to take full advantage of recent therapeutic advances and overcome remaining challenges. One key area requiring further study is the long-term safety and efficacy of recently developed treatments, particularly biologic-based therapies and novel topical agents such as roflumilast and ruxolitinib. Although these treatments have demonstrated significant short-term benefits, there is still a pressing need to study their long-term implications, including potential immunological consequences and the risk of resistance. This is particularly relevant given the chronic nature of many dermatological conditions, requiring ongoing treatment over long periods [49].

Personalized dermatology represents another promising avenue for future research. The advent of precision medicine has begun to transform oncology and other areas of medicine, yet its application in dermatology remains relatively underdeveloped. Future research should focus on integrating genetic, epigenetic, and biomarker-based approaches into dermatological practice to tailor treatments to individual patient profiles. This approach could improve treatment efficacy and minimize side effects by identifying which patients are most likely to respond to specific treatments [50].

Furthermore, significant gaps remain in our understanding of the pathogenesis of various skin diseases, particularly diseases such as psoriasis, AD, and melanoma. Although the role of the immune system in these diseases has been extensively studied, the precise triggers and mechanisms that initiate and maintain these immune responses are not fully understood. For example, in melanoma, the mechanisms underlying resistance to targeted therapies and immunotherapy remain a critical area of research. Consequently, overcoming these barriers could significantly improve patient outcomes [51].

The role of the skin microbiome in health and disease is also a growing area of interest. Despite the growing recognition of the importance of the microbiome, its precise contribution to the pathogenesis of skin diseases such as acne, atopic dermatitis, and psoriasis is still not fully understood. Future research should aim to elucidate the interactions between the skin microbiome and the host immune system, and how these interactions influence disease progression and treatment response. Furthermore, understanding how treatments, both topical and systemic, affect the skin microbiome may lead to the development of treatments that not only target the skin disease but also maintain or restore a healthy microbiome balance [87].

Emerging technologies such as artificial intelligence (AI) and machine learning offer exciting potential to revolutionize dermatology, particularly in diagnosis and treatment planning. For example, AI-based tools for skin cancer detection have shown promise, but further research is needed to validate these technologies and integrate them into clinical practice. Similarly, advances in imaging technologies and the identification of new biomarkers for early disease detection and treatment monitoring are critical areas for future research that could significantly improve the accuracy and effectiveness of dermatological care [88].

Finally, the psychosocial impact of chronic skin diseases is an area that has been relatively understudied in dermatology research. Conditions such as psoriasis, AD, and acne can have a significant impact on patients' mental health and overall quality of life. There is a pressing need for research that not only examines the physical manifestations of these diseases but also develops comprehensive care strategies that include psychological support, thereby improving overall treatment outcomes and patient quality of life [89].

Conclusion

This literature review highlights the multifaceted landscape of dermatology encompassing diverse subfields: from skin cancer detection and treatment to pediatric dermatology, and from cosmetic dermatology trends to the role of telemedicine. Through comprehensive exploration of recent advances, treatment modalities and emerging technologies, dermatologists can effectively navigate the complexities of diagnosing and managing various dermatologic conditions. Moreover, the integration of telemedicine offers promising avenues for expanding access to specialized care, particularly in underserved regions, while also addressing challenges related to the accuracy of diagnosis and patient privacy. As dermatologic research continues to evolve, it is imperative for healthcare providers to remain abreast of the latest developments and embrace innovative approaches to enhance patient outcomes and quality of life.

Funding. There was no external funding for this study.

Conflict of interest. None declared by the authors.

References

1. Zaheri S, Ali I. Recent Advances in Dermatology. *JP Medical Ltd.*, 2019.
2. Dildar M, Akram S, Irfan M, et al. Skin cancer detection: A review using deep learning techniques. *International Journal of Environmental Research and Public Health* 2021; 18(10): 5479. https://doi.org/10.3390/ijerph18105479
3. Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. *International Journal of Molecular Sciences* 2023; 24(17): 13313. https://doi.org/10.3390/ijms241713313
4. Pescitelli L, Rosi E, Ricceri F, et al. Novel therapeutic approaches and targets for the treatment of atopic dermatitis. *Current Pharmaceutical Biotechnology* 2021; 22(1): 73–84. https://doi.org/10.2174/1389201021666200611112755
5. Quddusi FI, Youssef MJ, Davis DMR. Dermatologic manifestations of systemic diseases in childhood. *Pediatrics in Review* 2021; 42(12): 655–671. https://doi.org/10.1542/pir.2020-000679
6. Sivesind TE, Szeto MD, Kim W, Dellavalle RP. Google trends in dermatology: Scoping review of the literature. *JMIR Dermatology* 2021; 4(1): e27712. https://doi.org/10.2196/27712
7. Deng X, Gould M, Ali MA. A review of current advances for wound healing: Biomaterial applications and medical devices. Journal of Biomedical Materials Research. *Part B, Applied Biomaterials* 2022; 110(11): 2542–2573. https://doi.org/10.1002/jbm.b.35086
8. Wolff H, Fischer TW, Blume-Peytavi U. The diagnosis and treatment of hair and scalp diseases. *Deutsches Arzteblatt*

International 2016; 113(21): 377–386. https://doi.org/10.3238/arztebl.2016.0377
9. Gilliam AE. Future directions in pediatric dermatology. *Pediatric Annals* 2005; 34(3), 240–242. https://doi.org/10.3928/0090-4481-20050301-12
10. Trettel A, Eissing L, Augustin M. Telemedicine in dermatology: Findings and experiences worldwide – A systematic literature review. *Journal of the European Academy of Dermatology and Venereology: JEADV* 2018; 32(2): 215–224. https://doi.org/10.1111/jdv.14341
11. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a Cancer Journal for Clinicians* 2018; 68(6): 394–424. https://doi.org/10.3322/caac.21492
12. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. *The Lancet. Oncology* 2002; 3(3): 159–165. https://doi.org/10.1016/s1470-2045(02)00679-4
13. Tschandl P, Rinner C, Apalla Z, et al. Human–computer collaboration for skin cancer recognition. *Nature Medicine* 2020; 26(8), 1229–1234. https://doi.org/10.1038/s41591-020-0942-0.
14. Cristescu MI, Popa LG, Cozma EC, et al. The Importance of in vivo reflectance confocal microscopy in a case of desmoplastic melanoma. *Life* 2024; 14(5):574. https://doi.org/10.3390/life14050574
15. Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nature Reviews. *Drug Discovery* 2018; 17(7): 509–527. https://doi.org/10.1038/nrd.2018.75
16. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 2015; 33(25): 2780–2788. https://doi.org/10.1200/JCO.2014.58.3377
17. Cohen DK, Goldberg DJ. Mohs micrographic surgery: Past, present, and future. *Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery* 2019; 45(3): 329–339. https://doi.org/10.1097/DSS.0000000000001701
18. Chia HY, Koh SL, Theng TS, Chong WS. Topical photodynamic therapy in the treatment of basal cell carcinoma in Singaporean Chinese patients. *Indian Journal of Dermatology, Venereology and Leprology* 2015; 81(2): 151–154. https://doi.org/10.4103/0378-6323.152180
19. Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. *The New England Journal of Medicine* 2015; 372(26): 2521–2532. https://doi.org/10.1056/NEJMoa1503093
20. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. *Cancer* 2012; 12(4): 252–264. https://doi.org/10.1038/nrc3239
21. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *The New England Journal of Medicine* 2015; 373(1): 23–34. https://doi.org/10.1056/NEJMoa1504030
22. Slominski RM, Kim T-K, Janjetovic Z, et al. Malignant melanoma: An overview, new perspectives, and vitamin D signaling. *Cancers* 2024; 16(12): 2262. https://doi.org/10.3390/cancers16122262
23. Brożyna AA, Hoffman RM, Slominski AT. Relevance of vitamin D in melanoma development, progression and therapy. *Anticancer Research* 2020; 40(1): 473–489. https://doi.org/10.21873/anticanres.13976
24. Slominski AT, Brożyna AA, Kim TK, et L. CYP11A1-derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas. *International Journal of Oncology* 2022; 61(2), 96. https://doi.org/10.3892/ijo.2022.5386
25. Slominski AT, Kim TK, Janjetovic Z, et al. Biological effects of CYP11A1-derived vitamin D and lumisterol metabolites in the skin. *Journal of Investigative Dermatology* 2024. https://doi.org/10.1016/j.jid.2024.04.022
26. Slominski A, Wortsman J. Neuroendocrinology of the skin. *Endocrine Reviews* 2000; 21(5): 457–487. https://doi.org/10.1210/edrv.21.5.0410
27. Anderson ZT, Dawson AD, Slominski AT, Harris ML. Current insights into the role of neuropeptide Y in skin physiology and pathology. *Frontiers in Endocrinology* 2022; 13: 838434. https://doi.org/10.3389/fendo.2022.838434
28. Slominski AT, Slominski RM, Raman C, et al. Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides. American Journal of Physiology. *Cell Physiology* 2022; 323(6): C1757–C1776. https://doi.org/10.1152/ajpcell.00147.2022
29. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues in Clinical Neuroscience* 2006; 8(4): 383–395. https://doi.org/10.31887/DCNS.2006.8.4/ssmith
30. Slominski AT, Zmijewski MA, Plonka PM, et al. How UV light touches the brain and endocrine system through skin, and why. *Endocrinology* 2018; 159(5): 1992–2007. https://doi.org/10.1210/en.2017-03230
31. Slominski RM, Chen JY, Raman C, Slominski AT. Photo-neuro-immuno-endocrinology: How the ultraviolet radiation regulates the body, brain, and immune system. *Proceedings of the National Academy of Sciences* 2024; 121(14). https://doi.org/10.1073/pnas.2308374121
32. Chen Y, Lyga J. Brain-skin connection: Stress, inflammation and skin aging. *Inflammation & Allergy Drug Targets* 2014; 13(3): 177–190. https://doi.org/10.2174/1871528113666140522104422
33. Furue K, ItoT, Tsuji G, et al. Psoriasis and the TNF/IL23/IL17 axis. *Giornale italiano di Dermatologia e Venereologia : Organo Ufficiale, Societa Italiana di Dermatologia e Sifilografia* 2019; 154(4): 418–424. https://doi.org/10.23736/S0392-0488.18.06202-8
34. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *The Journal of Allergy and Clinical Immunology* 2017; 140(3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004
35. Gholami A, Vafaeian A, Daneshpazhooh M, et al. Treatment resistance to TNF-α inhibitors in patients with psoriasis. *Dermatologic Therapy* 2023 (1). https://doi.org/10.1155/2023/7399468
36. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. *Journal of the American Academy of Dermatology* 2008; 58(1): 106–115. https://doi.org/10.1016/j.jaad.2007.09.010
37. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. *The British Journal of Dermatology* 2013;168(2): 412–421. https://doi.org/10.1111/bjd.12110
38. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. *Lancet* 2015; 386(9993): 541–551. https://doi.org/10.1016/S0140-6736(15)60125-8
39. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. *The British Journal of Dermatology* 2012; 167(3): 668–677. https://doi.org/10.1111/j.1365-2133.2012.11168.x
40. Malara G, Politi C, Trifirò C, ey al. Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study. *Acta dermato-venereologica* 2021; 101(9): adv00545. https://doi.org/10.2340/00015555-3846
41. Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. *Journal of the European Academy of Dermatology and Venereology: JEADV* 2017; 31(10): 1616–1626. https://doi.org/10.1111/jdv.14433
42. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *The Journal of Allergy and Clinical Immunology* 2017; 140(3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004s
43. Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: Proposed algorithm for treatment and management. *Journal of Psoriasis and Psoriatic Arthritis* 2019; 4(2): 70–80. https://doi.org/10.1177/2475530318810851

44. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. *The British Journal of Dermatology* 2012; 167(3): 668–677. https://doi.org/10.1111/j.1365-2133.2012.11168.x
45. Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. *Drug design, development and therapy* 2016; 10: 1763–1770. https://doi.org/10.2147/DDDT.S108115
46. Guttman-Yassky E, Waldman A, Ahluwalia J, et al. Atopic dermatitis: Pathogenesis. *Seminars in Cutaneous Medicine and Surgery* 2017; 36(3): 100–103. https://doi.org/10.12788/j.sder.2017.036
47. Weidinger S, O'Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. *Journal of Allergy and Clinical Immunology* 2008; 121(5): 1203-1209.e1. https://doi.org/10.1016/j.jaci.2008.02.014
48. Weidinger S, Novak N. Atopic dermatitis. *Lancet* 2016; 387(10023): 1109–1122. https://doi.org/10.1016/S0140-6736(15)00149-X
49. Simpson EL, Kircik L, Blauvelt A, et al. Ruxolitinib cream in adolescents/adults with atopic dermatitis meeting severity thresholds for systemic therapy: Exploratory analysis of pooled results from two Phase 3 studies. *Dermatology and Therapy* 2024; https://doi.org/10.1007/s13555-024-01219-8
50. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. Journal of the American Academy of *Dermatology* 2021; 85(4): 863–872. https://doi.org/10.1016/j.jaad.2021.04.085
51. Simpson EL, Thyssen JP, Silverberg JI, et al. Ruxolitinib cream for the treatment of atopic dermatitis: A phase 3 randomized trial. *Lancet* 2021; 398(10301): 2331-2341.
52. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. *Expert Review of Clinical Immunology* 2017; 13(1): 15–26. https://doi.org/10.1080/1744666X.2016.1212660
53. Sidbury R, Davis DM, Cohen DE, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. *Journal of the American Academy of Dermatology* 2014; 71(2): 327–349. https://doi.org/10.1016/j.jaad.2014.03.030
54. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. *The New England Journal of Medicine* 2016; 375(24): 2335–2348. https://doi.org/10.1056/NEJMoa1610020
55. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *The New England Journal of Medicine* 2014; 371(2): 130–139. https://doi.org/10.1056/NEJMoa1314768
56. Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial. *JAMA Dermatology* 2020; 156(12): 1333–1343. https://doi.org/10.1001/jamadermatol.2020.3260
57. McDowell L, Olin B. Crisaborole: A novel nonsteroidal topical treatment for atopic dermatitis. The Journal of Pharmacy Technology: *JPT: official publication of the Association of Pharmacy Technicians* 2019; 35(4): 172–178. https://doi.org/10.1177/8755122519844507
58. Bolognia JL, Schaffer JV, Cerroni L, Callen JP. *Dermatology* 2018.
59. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis and rheumatism* 1997; 40(9): 1725. https://doi.org/10.1002/art.1780400928
60. Kuhn A, Wozniacka A, Szepietowski JC, et al. Photoprovocation in cutaneous lupus erythematosus: A multicenter study evaluating a standardized protocol. *The Journal of Investigative Dermatology* 2011; 131(8): 1622–1630. https://doi.org/10.1038/jid.2011.101
61. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. *Autoimmunity Reviews* 2005; 4(5): 253–263. https://doi.org/10.1016/j.autrev.2004.10.003
62. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: A review. *Endocrinology and Metabolism Clinics of North America* 2013; 42(4): 869–898. https://doi.org/10.1016/j.ecl.2013.07.004
63. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. *Clinical Diabetes: A publication of the American Diabetes Association* 2015; 33(1): 40–48. https://doi.org/10.2337/diaclin.33.1.40
64. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. *The New England Journal of Medicine* 1991; 325(21): 1487–1498. https://doi.org/10.1056/NEJM199111213252107
65. Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). *Journal of the European Academy of Dermatology and Venereology: JEADV* 2020; 34(9): 1900–1913. https://doi.org/10.1111/jdv.16752
66. Werth VP, Askanase AD, Lundberg IE. Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis. *International Journal of Women's Dermatology* 2021; 7(5Part A): 583–587. https://doi.org/10.1016/j.ijwd.2021.09.002
67. Leal JM, de Souza GH, Marsillac PF, Gripp AC. Skin manifestations associated with systemic diseases - Part II. *Anais Brasileiros de Dermatologia* 2021; 96(6): 672–687. https://doi.org/10.1016/j.abd.2021.06.003
68. Carruthers A, Kane MA, Flynn TC, et al. The convergence of medicine and neurotoxins: A focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: Part I: Botulinum toxin in clinical and cosmetic practice. *Dermatologic Surgery: official publication for American Society for Dermatologic Surgery* 2013; 39(3 Pt 2): 493–509. https://doi.org/10.1111/dsu.12147
69. Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A comprehensive review. *Dermatologic Surgery: official publication for American Society for Dermatologic Surgery* 2017; 43(3): 321–339. https://doi.org/10.1097/DSS.0000000000000924
70. Benar H, Benar EB. A new nonsurgical combination approach for skin tightening and remodeling; Endoskin—A comparative study. *Journal of Cosmetic Dermatology* 2024. https://doi.org/10.1111/jocd.16306
71. O'Connor AA, Lowe PM, Shumack S, Lim AC. Chemical peels: A review of current practice. *The Australasian Journal of Dermatology* 2018; 59(3): 171–181. https://doi.org/10.1111/ajd.12715
72. Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: An evidence-based review. *Plastic and Reconstructive Surgery* 2010; 125(1): 372–377. https://doi.org/10.1097/PRS.0b013e3181c2a583
73. Carruthers A, Sadick N, Brandt F, et al. Evolution of facial aesthetic treatment over five or more years: A retrospective cross-sectional analysis of continuous onabotulinumtoxinA treatment. *Dermatologic Surgery: official publication for American Society for Dermatologic Surgery* 2015; 41(6): 693–701. https://doi.org/10.1097/DSS.0000000000000340
74. Machado RA, Oliveira LQ, Martelli-Júnior H, et al. Adverse reactions to the injection of face and neck aesthetic filling materials: A systematic review. *Medicina Oral, Patologia Oral y Cirugia Bucal* 2023; 28(3): e278–e284. https://doi.org/10.4317/medoral.25713

75. Husein-ElAhmed H, Steinhoff M. Laser and light-based therapies in the management of rosacea: An updated systematic review. *Lasers in Medical Science* 2021; 36(6): 1151–1160. https://doi.org/10.1007/s10103-020-03200-1
76. Boateng J, Catanzano O. Advanced therapeutic dressings for effective wound healing--A review. *Journal of Pharmaceutical Sciences* 2015; 104(11): 3653–3680. https://doi.org/10.1002/jps.24610
77. Hermans MH. Silver-containing dressings and the need for evidence. *The American Journal of Nursing* 2006; 106(12): 60–69. https://doi.org/10.1097/00000446-200612000-00025
78. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. *Wound Repair and Regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society* 2008; 16(5): 585–601. https://doi.org/10.1111/j.1524-475X.2008.00410.x
79. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet-rich plasma for treating chronic wounds. *The Cochrane Database of Systematic Reviews* 2016(5); CD006899. https://doi.org/10.1002/14651858.CD006899.pub3
80. Murphy SV, Atala A. 3D bioprinting of tissues and organs. *Nature Biotechnology* 2014; 32(8): 773–785. https://doi.org/10.1038/nbt.2958
81. Kim JY, Suh W. Stem cell therapy for dermal wound healing. *International Journal of Stem Cells* 2010; 3(1): 29–31. https://doi.org/10.15283/ijsc.2010.3.1.29
82. Apelqvist J. Diagnostics and treatment of the diabetic foot. *Endocrine* 2012; 41(3): 384–397. https://doi.org/10.1007/s12020-012-9619-x
83. Sharma R, Sharma SK, Mudgal SK, et al. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. *Scientific Reports* 2021; 11(1): 2189. https://doi.org/10.1038/s41598-021-81886-1
84. Guo S, Dipietro LA. Factors affecting wound healing. *Journal of Dental Research* 2010; 89(3): 219–229. https://doi.org/10.1177/0022034509359125
85. Ojeh N, Pastar I, Tomic-Canic M, Stojadinovic O. Stem cells in skin regeneration, wound healing, and their clinical applications. *International Journal of Molecular Sciences* 2015; 16(10): 25476-25501. https://doi.org/10.3390/ijms161025476
86. Drakos A, Vender R, Torres T. Topical roflumilast for the treatment of psoriasis. *Expert Review of Clinical Immunology* 2023; 19(9): 1053–1062. https://doi.org/10.1080/1744666X.2023.2219897
87. Eichenfield LF, Simpson EL, Papp K, et al. Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: Pooled results from two randomized Phase 3 studies. *Am J Clin Dermatol*. 2024; 25: 669–683. https://doi.org/10.1007/s40257-024-00855-2
88. Brownstone N. Psoriasis therapies in 2024 and beyond. Dermatology *Times* 2024. URL: https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond
89. Gold LS, Adam DN, Albrecht L, et al. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. *Journal of the American Academy of Dermatology* 2024; https://doi.org/10.1016/j.jaad.2024.03.030

Authors:
Kirolos Eskandar - Physician, Department of General Medicine, https://orcid.org/0000-0003-0085-3284